Q3 Earnings Forecast for ODTX Issued By HC Wainwright

Key Points

• HC Wainwright expects Odyssey Therapeutics to report a Q3 2026 loss of $1.13 per share and maintains a “Buy” rating with a $44 price target. The firm forecasts continued losses through 2030, including $6.13 per share for full-year 2026.
• Analyst sentiment is broadly positive, with six Buy ratings, one Hold, and one Sell; MarketBeat lists a consensus “Moderate Buy” rating and an average price target of $35.75.
• ODTX recently traded at $24.36, with a $1.17 billion market capitalization and a 52-week range of $15.10 to $28.00. The company reported a quarterly loss of $1.74 per share in its latest earnings release.

Odyssey Therapeutics, Inc. (NASDAQ:ODTX - Free Report) - Research analysts at HC Wainwright issued their Q3 2026 earnings per share estimates for shares of Odyssey Therapeutics in a report released on Thursday, August 27th. HC Wainwright analyst E. Bodnar expects that the company will earn ($1.13) per share for the quarter. HC Wainwright currently has a "Buy" rating and a $44.00 price target on the stock. The consensus estimate for Odyssey Therapeutics' current full-year earnings is ($5.99) per share. HC Wainwright also issued estimates for Odyssey Therapeutics' Q4 2026 earnings at ($1.19) EPS, FY2026 earnings at ($6.13) EPS, FY2027 earnings at ($5.18) EPS, FY2028 earnings at ($4.93) EPS, FY2029 earnings at ($4.68) EPS and FY2030 earnings at ($4.15) EPS.

ODTX has been the subject of several other research reports. Wall Street Zen lowered shares of Odyssey Therapeutics from a "hold" rating to a "sell" rating in a research note on Saturday, June 20th. Zacks Research raised shares of Odyssey Therapeutics to a "hold" rating in a research note on Wednesday, June 3rd. JPMorgan Chase & Co. raised their price target on shares of Odyssey Therapeutics from $26.00 to $29.00 and gave the stock an "overweight" rating in a report on Friday, August 7th. Oppenheimer reaffirmed an "outperform" rating and issued a $40.00 price target on shares of Odyssey Therapeutics in a research note on Thursday, June 18th. Finally, Cantor Fitzgerald started coverage on shares of Odyssey Therapeutics in a report on Tuesday, June 2nd. They set an "overweight" rating on the stock. Six investment analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the stock. According to MarketBeat, Odyssey Therapeutics has a consensus rating of "Moderate Buy" and a consensus target price of $35.75.

Odyssey Therapeutics Price Performance

Odyssey Therapeutics stock opened at $24.36 on Monday. The company has a market cap of $1.17 billion and a PE ratio of -3.60. Odyssey Therapeutics has a 52-week low of $15.10 and a 52-week high of $28.00. The stock's 50 day simple moving average is $19.68.

Odyssey Therapeutics (NASDAQ:ODTX - Get Free Report) last issued its earnings results on Wednesday, August 5th. The company reported ($1.74) earnings per share for the quarter.

About Odyssey Therapeutics

Odyssey Therapeutics Inc is a clinical-stage biopharmaceutical company seeking to transform the standard of care for patients suffering from autoimmune and inflammatory diseases by developing medicines which are designed to precisely target disease pathology. Odyssey Therapeutics Inc is based in BOSTON.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source